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Abstract 
PURPOSE OF THE STUDY:  Many breast cancer patients report depressive 
symptoms at diagnosis.  Although depressive symptoms improve, it is unknown whether 
women fully recover into the survivorship years, as previous studies have been cross-
sectional or only short-term.  RESEARCH METHOD: Breast cancer patients were 
accrued following surgery and prior to adjuvant therapy (baseline) and then followed for 
5 years.  Measures of psychological and physical functioning (both patient and nurse-
rated) were used.  Baseline CES-D scores (11-item version) were used to classify patients 
as clinically depressed (scores > 10; n = 45; DEP) or non-depressed (scores < 10; n = 
182; NON-DEP).  FINDINGS: Using mixed model analyses, trajectories of physical and 
psychological functioning over 5 years for the groups were compared.  For physical 
functioning (KPS and signs/symptoms of illness/treatment), the DEP group had poorer 
outcomes from baseline through 12 months (ps < .01).  Over time, both groups gradually 
improved in physical functioning in a similar pattern (ps > .12). The psychological 
trajectories--depressive symptoms (CES-D), stress (IES), and quality of life (SF-36 
mental and physical components)--were of similar form.  Across outcomes, the DEP 
group had poorer functioning at baseline (ps < .001) and this difference was maintained 
through 24 months (ps < .05).  The groups were equivalent thereafter (ps > .39). 
IMPLICATIONS: Significant depressive symptomatology at cancer diagnosis portends 
impaired functioning for years.  For such individuals, physical symptoms remain 
 significantly elevated through 12 months, and poorer quality of life and high levels of 
cancer-specific stress extend for another year.  Only after 2 years do women depressed at 
diagnosis appear to attain a level of recovery similar to that of those not depressed at 
diagnosis.  Thus, interventions are needed for patients vulnerable to slowed physical and 
psychological recovery from cancer.   
 
Introduction 
The human costs of cancer are overwhelming.  The earliest of clinical studies 
described an ‘existential plight’ at diagnosis, characterized by bringing extreme shock, 
disbelief, and emotional turmoil (Weisman & Worden, 1976).  Although negative events 
do not always produce stress, data from many studies document severe acute stress at 
cancer diagnosis and treatment (e.g., Andersen, Anderson, & deProsse, 1989; Maunsell, 
Brisson, & Deschenes, 1992; Stanton, Danoff-Burg, & Huggins, 2002).  It is also clear 
that even after lengthy, difficult treatments have ended, individuals still report disruptions 
in major life areas and, for some, continuing problems with emotional distress (Carlson et 
al., 2004; Engel et al., 2003), role and social functioning (Kopp, Bauhofer, & Koller, 
2004), fatigue (Anderson et al., 2003; Servaes, Verhagen, & Bleijenberg, 2002), pain 
(Dalton, Keefe, Carlson, & Youngblood, 2004), and sleep disturbance (Bower et al., 
2000; Savard, Simard, Blanchet, Ivers, & Morin, 2001).     
Cancer and comorbid Depression 
The lifetime prevalence of any psychiatric disorder for those with a chronic 
medical condition is higher—42%—than is found for the general population (i.e., 33%; 
Wells, Golding, & Burnham, 1988).  Mental health disorders among cancer patients are 
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 prevalent, largely unrecognized, and in turn, untreated.  In studies of the last 25 years, it 
is consistently estimated that 30-50% of cancer patients meet criteria for mood or anxiety 
disorders (Burgess et al., 2005; Derogatis & Melisaratos, 1983; Zabora, Brintzenhofssoc, 
Curbow, Hooker, & Piantadosi, 2001), with depression being the most common (Massie, 
2004; van't Spiker, Trijsburg, & Duivenvoorden, 1997).  Specifically, estimates for major 
depressive disorder (MDD) are 22 to 29% for patients with early stage disease (Raison & 
Miller, 2003), and range from 8 to 40% for patients with advanced disease (Hotopf, 
Chidgey, Addington-Hall, & Lan Ly, 2002), and increase further with recurrence 
(Burgess et al., 2005). Among common site for cancer among women, such as breast or 
gynecologic cancers, Zabora et al. (2001) found prevalence of 33% and 30%, 
respectively.  Schairer et al. (2006) reported that breast cancer survivors may have an 
increased risk for suicide, even among those diagnosed as long as 25 years previously.   
Finally, other morbidity comes with depression, such as comorbid anxiety (e.g. Dausch et 
al., 2004; Schwartz & Drotar, 2006), poorer quality of life (e.g. Deshields, Tibbs, Fan, & 
Taylor, 2006; Peters & Sellick, 2006; Yen et al., 2006), fatigue (e.g. Sadler et al., 2002; 
Smith, Gomm, & Dickens, 2003), and more distress from physical symptoms (e.g. 
Mystakidou et al., 2005).   
Unfortunately, cancer patients with comorbid depression are not readily 
identified.  For example, among 112 women with major depression undergoing cancer 
treatment, Ell and colleagues (2005) found that few were being treated: only 12% were 
receiving antidepressants and only 5% receiving psychological therapy.  Excepting the 
most obvious symptoms (e.g., suicidal ideation, Oquendo et al., 2004), indications of 
psychopathology may not be familiar to oncology professionals, there may be insufficient 
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 time for analysis during medical appointments, symptoms may be trivialized as a 
‘normal’ reaction, or, even when recognized they may seen as due only to impaired 
physical status (Evans et al., 2005).  Indeed, studies show that oncologists and nurses 
detect depressive symptoms in only a third of the patients who have them, and, further, 
underestimate symptom severity (Keller et al., 2000; McDonald et al., 1999; Newell, 
Sanson-Fisher, Girgis, & Bonaventura, 1998).  Even when treated with antidepressant 
medication, patients may not receive an adequate dose (Ashbury et al., 2003; Sharpe et 
al., 2004).   
Little is known about how those with elevated depressive symptoms during the 
diagnostic or treatment period fare with follow up.  Data come only from cross-sectional 
(e.g. Golden-Kreutz & Andersen, 2004) or short-term follow-up studies (Akechi et al., 
2006; Kurtz, Kurtz, Stommel, Given, & Given, 2002). One study compared rates of 
depressive symptoms in cancer survivors to similar-aged individual without cancer and 
found no differences between groups at 8 years after diagnosis (Schroevers, Ranchor, & 
Sanderman, 2006).  However, a meta-analysis suggests that depression does not decline 
(van't Spiker et al., 1997).   
 
Method 
Data was used from ongoing follow up of patients from a randomized clinical trial 
(Andersen et al., 2004) to examine the stability of depressive symptomatology and 
concurrent life disruption.  Newly diagnosed breast cancer patients  (N = 227) with 
regional disease were accrued after diagnosis but prior to adjuvant therapy, assessed at 
that time (baseline), and then followed for 5 years.  The sample was primarily Caucasian 
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 (90%), middle aged (M = 51, SD = 11 years), married or partnered (74%), with some 
college (M = 14 years of education, SD = 3), and above average income (median = 
$51,000).  The majority of individuals was diagnosed with Stage II disease (90%), had a 
mastectomy (57%) versus lumpectomy (43%), was pre-menopausal (54%), and had 
positive nodal status (68%). Assessments included measures of psychological and 
physical functioning. Women (n = 45; DEP) meeting the clinically significant cutoff for 
elevated depressive symptoms [scores ≥ 10 on the 11-item Center for Epidemiological-
Studies Depression Scale (CES-D)] at baseline were compared to the remaining patients 
scoring <10 (n = 182; NON-DEP).   
Mixed-effects modeling was used to compare the two groups.  This analysis is 
advantageous for analyzing longitudinal data as it accounts for correlations among 
repeated assessments within an individual and allows the number of repeated assessments 
to vary across individuals.  Using this framework, fixed-effects were estimated to test for 
average group differences in baseline and changes over time. Six fixed effects were 
tested: Intercept, Linear Slope, Quadratic Change, and Group differences in Intercept, 
Slope, and Quadratic Change.  The form of change, linear versus quadratic, was 
determined by comparison of relative fit of models using a likelihood ratio test.  If the fit 
of the quadratic model was not significantly better (α=.05), the linear model was retained.  
No sociodemographic (i.e. age, education level, marital status, race, income, and 
intervention arm), disease (i.e. stage and nodal status), or treatment (i.e. lumpectomy vs. 
mastectomy, chemotherapy, radiation, and hormone therapy) variables were found to 
differ between the groups in the preliminary analyses; therefore, none were included in 
the multilevel models.  Time was coded in months.   
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 The follow-up trajectory of psychological and physical functioning of those 
women who reported elevated depressive symptoms at breast cancer diagnosis was 
compared with the trajectory of those without symptoms at diagnosis.  Preliminary 
analyses revealed that, across groups, psychological and physical functioning improved 
primarily within the first 24 months after diagnosis.  Based on this general pattern, one 
model was estimated for each outcome, describing the period of chemotherapy and the 
year thereafter (pre-chemotherapy baseline, 4, 8, 12, 18, and 24-month assessments).  
Figures provide graphical representation of the predicted trajectories from the mixed 
model analyses.  A linear model was used for health status and a quadratic model for all 
others. 
 
Results 
Depressive Symptoms 
Depressive symptoms were measured with the CES-D.   As expected, the score 
for the DEP group was significantly higher (“worse”) at baseline, with a mean score of 
11.6 as compared to the NON-DEP group, whose average was 4.7, or more than half of 
the DEP group (see Figure 2).  A significant quadratic change over time was observed for 
the DEP group (p < .001).  This indicates that, for the DEP group, depressive symptoms 
declined below the clinical cutoff of 10, plateaued, and increased with a nadir (the lowest 
point) seen around 18 months (p < .001) at a score of 7.1.  In contrast, the NON-DEP 
group showed little change over time (Difference in Group X Quadratic Time, p = .002), 
with their average at 4 for the two year period.  Follow-up ANOVAs reveal significant 
group differences at each time point.     
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 Figure 2.  Depressive Symptoms from baseline to 24 months post-diagnosis, 
categorized by group.   
 
Stress 
 Cancer-specific stress was measured with the Impact of Events Scale (IES; 
Horowitz, Wilner, & Alvarez, 1979).  Total scores range from 0 to 75 and scores above 
19 reflect clinically relevant levels of traumatic stress (Horowitz, 1982).   The result of 
the mixed model analysis was similar to the results for depressive symptoms (see Figure 
3).   Both groups scored above the cutoff, but the DEP group scored significantly higher 
(“worse”) at baseline, with a mean predicted score of 37, as compared to the NON-DEP 
group, with a mean predicted score of 22 (p < .001).  A significant quadratic change was 
observed for the DEP group (p < .001) but the pattern of change did not differ by group 
(p = .083).  For both the DEP and NON-DEP group, stress declined, plateaued, and 
increased with a nadir seen at 18 months.  Follow-up ANOVAs revealed significant 
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 group differences at each time point.  Notably, the DEP group remained above the 
clinically significant cut-off of 19 throughout the 2 year follow-up.   
Figure 3.  Cancer-specific stress from baseline to 24 months post-diagnosis, 
categorized by group.   
 
Quality of Life:  Mental and Physical Health 
 Quality of life was assessed using the mental and physical component summary of 
the Medical Outcomes Study SF-36 [MCS and PCS respectively; (Ware, Kosinski, & 
Keller, 1994)]. Higher scores on the SF-36 indicate better, and not worse, functioning.  In 
the model, the score for the DEP group was significantly lower (“worse”) at baseline (p < 
.001), with an average score 2 standard deviations (or 20 points) lower than the 
population mean of 50 (Ware et al., 1994), as compared to the NON-DEP group, whose 
scored was approximately 0.5 SD lower than the population mean.  A significant 
quadratic change was observed for the DEP group (p < .001) and the pattern of change 
differed by group (p < .001).  For the DEP group, mental health quality of life improved, 
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 plateaued, and decreased somewhat with a nadir seen around 18 months (p < .001). In 
contrast, the NON-DEP group showed less change over time (p < .001) and remained in 
the range of 50.  Follow-up ANOVAs revealed significant group differences at each time 
point.   
Figure 4.  Mental health quality of life from baseline to 24 months post-diagnosis, 
categorized by group.   
 
 Results for physical health quality of life are somewhat different.  There were no 
significant differences for the baseline PCS (p = .319).  Both groups scored 
approximately one standard deviation (or 10 points) below the population mean of 50.  
The DEP group showed no statistically significant improvement over time (p = .373; see 
Figure 5).  However, the NON-DEP group life improved, plateaued, and decreased 
somewhat with a nadir seen around 18 months (p = .029).  Follow-up ANOVAs reveal 
group differences at each time point.  In summary, although both groups had poor 
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 physical health quality of life at baseline, the NON-DEP group exhibited faster recovery, 
with scores approaching the population mean.   
Figure 5.  Physical health quality of life from baseline to 24 months post-diagnosis, 
categorized by group.   
 
Physical Functioning 
 Physical functioning included two measures.  The Karnofsky Performance Status 
Scale (KPS; Karnofsky & Burchenal, 1949) measures performance status.  Higher scores 
indicate better functional status (e.g., 90 = Able to carry on normal activity, minor 
signs/symptoms of disease; 80 = Normal activity with effort, some signs/symptoms of 
disease).  In these analyses, a linear model was used.  The DEP group reported worse 
functioning at baseline, with an average predicted score of 81 as compared to the NON-
DEP group, whose mean predicted score was 86 (p < .001; see Figure 6).  By the 24-
month assessment, both groups had reached a mean predicted score of 90.  A significant 
linear change was observed for the DEP group (p < .001) and the pattern of change 
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 differed by group (p < .001).  The NON-DEP group showed less change over time (p < 
.01).  Follow-up ANOVAs reveal group differences up to the 12-month assessment.   
Figure 6.  Health status from baseline to 24 months post-diagnosis, categorized by 
group.   
 
The second measure of physical functioning rates signs and symptoms of 
toxicities related to cancer treatments (SWOG; Moinpour et al., 1989).  Higher scores 
indicate poorer functioning.  In these analyses, a linear model was used.  The DEP group 
reported worse functioning at baseline as compared to the NON-DEP group (p < .01; see 
Figure 7).  There were no significant differences in time or its interaction with group (ps 
> .3).  Follow-up ANOVAs reveal group differences up to the 12-month assessment. 
Thus, physical functioning was worse in the DEP group and this difference appeared to 
be maintained throughout the first year after cancer diagnosis.   
Figure 7.  Signs/symptoms of treatment toxicities from baseline to 24 months post-
diagnosis, categorized by group.   
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Discussion 
Psychological stress is a near-universal experience after a cancer diagnosis.  For 
some, stress can develop into a depressive disorder.  If untreated, depression can 
negatively impact quality of life, treatment adherence, physical health status, and even 
disease outcome.  Our data indicate that women with elevated depressive symptoms at 
breast cancer diagnosis continued to report difficulties in psychological and physical 
functioning for the next two years.  The DEP group had more cancer-specific traumatic 
stress and poorer mental health quality of life at baseline.  The rates of improvement for 
psychological functioning within the groups differed as well. While the DEP group 
improved at a significantly faster rate, it was unable to reach the same level of recovery 
as the NON-DEP group.  Regarding physical health quality of life, the NON-DEP group 
improved over time, while the DEP group did not.   
Differences in physical functioning were found between the two groups in the 
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 first year after diagnosis.  It is interesting to note that although the two groups had similar 
physical functioning after the first 12 months, the DEP group continued to report worse 
psychological functioning and poorer quality of life for an additional year.   
The mechanisms of the development/maintenance of depression in cancer patients 
are not well understood.  For example, those fatigued from cancer treatments may 
withdraw from pleasurable activities, which promotes the occurrence/maintenance of 
depression (Jacobson et al., 1996).  It is also plausible that those with a history of 
depression generate may generate more stress when facing a current negative event, 
which in turn makes them more susceptible to a recurrence of a depressive episode 
(Hammen).  In addition, biological pathways, such as inflammation, may contribute to 
the development of depression.  Such an immune response could be triggered by stress, 
disease processes, and/or cancer treatment.   
Psychological interventions for cancer patients can reduce stress and improve 
quality of life (Andersen et al., 2004).  A meta-analysis of psychooncological 
interventions suggested that they are more effective for alleviating anxiety than they are 
for depression (Meyer & Mark, 1995).  Thus, interventions designed specifically for 
depressed cancer patients may be needed.  Also, our data support the identification and 
treatment of individuals suffering from high levels of psychological distress at cancer 
diagnosis.  Additionally, populations with risk factors associated with high psychological 
distress, such as those who do not have a romantic partner, are of low socioeconomic 
status, or are younger, should also be targeted for intervention (Spijker, Trijsburg, & 
Duivenvoorden, 1997).  Thus, interventions are needed for patients vulnerable to slowed 
physical and psychological recovery from cancer.   
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